HMGCR inhibition, corresponding to a 1-SD reduction in LDL-C, was significantly causally associated with a lower risk of migraine (FinnGen dataset: OR = 0.64, [95% CI, 0.46–0.88], p = 0.0006; Choquet dataset: OR = 0.78, [95% CI, 0.60–1.01], p = 0.06; pooled estimates: OR = 0.73, [95% CI, 0.60–0.89], p = 0.0016). Here, HMGCR is linked to migraine disorder.